CombiMatrix Molecular Diagnostics is talking to both Laboratory Corporation of America and Quest Diagnostics, as well as a "few others" as potential customers or distributors of its cancer molecular diagnostics, PGX Reporter learned this week.
According to CombiMatrix vice president Bret Undem, CMD hopes to obtain clinical laboratory improvement amendment (CLIA) certification by the end of the year, which is when it plans to have its first microarray-based diagnostic products ready.